HIms and Hers shares drop after FDA says Lilly's weight-loss drug not in shortage
Shares in telehealth group Hims & Hers Health (NYSE:HIMS) dropped in premarket US trading on Thursday after federal drug regulators said Eli Lilly (NYSE:LLY)'s blockbuster weight-loss and diabetes medications are no longer considered to be in shortage.
Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
Anticipating a 35% CAGR in 2025, Hims & Hers is poised for substantial growth. Read why I maintain my strong buy rating on ...
The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...
Hims & Hers (NASDAQ: HIMS) stock has done well since the company went public a few years ago. It has soared by over 193% in ...
Hims & Hers is a fantastic value despite its high on-the-surface P/E ratio and valuation metrics. Click here to read why HIMS ...
Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed ...
Hims & Hers is making GLP-1 weight loss medications more accessible with a 50% discount for front-line heroes. Mihir Gandhi ...
Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks.
Stocks were mixed Thursday as traders digested a greater-than-expected increase in weekly jobless claims and awaited the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback